About this Research Topic
This Research Topic aims to give a broad overview of the emerging technologies, prospects, but also limitations for blood-based biomarkers to assess the immunologic status and guide therapy of cancer patients. These include both cell-based (e.g. flow cytometry) as well as molecular assays, either at the proteomic, transcriptomic or genetic level, assessed directly ex vivo of after in vitro manipulation.
We welcome the submission of Original Research, Review, or Perspective articles including, but not limited to:
1. Cellular parameters as predictive and prognostic biomarkers in various cancers
2. Molecular assays at the proteomic, transcriptomic or genetic level with potential future applications in patient stratification and therapy selection
3. Studies on the relationship between the tumor microenvironment and blood immunologic characteristics of cancer patients
4. Studies on disease-specific patterns of immune dysregulation as assessed using blood-based methods in various cancers
5. Any method (pharmacologic or other) to restore immunologic defects, as assessed using peripheral blood, and enhance the efficacy of immunotherapy in cancer patients, including preclinical and clinical studies.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
We welcome the submission of Original Research, Review, or Perspective articles including, but not limited to:
1. Cellular parameters as predictive and prognostic biomarkers in various cancers
2. Molecular assays at the proteomic, transcriptomic or genetic level with potential future applications in patient stratification and therapy selection
3. Studies on the relationship between the tumor microenvironment and blood immunologic characteristics of cancer patients
4. Studies on disease-specific patterns of immune dysregulation as assessed using blood-based methods in various cancers
5. Any method (pharmacologic or other) to restore immunologic defects, as assessed using peripheral blood, and enhance the efficacy of immunotherapy in cancer patients, including preclinical and clinical studies.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: immune cell subsets, cellular immunity, immunomodulation, immunologic biomarkers, liquid biopsy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
